222 related articles for article (PubMed ID: 16432856)
1. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
Ling S; Joshua DE; Gibson J; Young G; Iland H; Watson G; Ho PJ
Am J Hematol; 2006 Feb; 81(2):110-4. PubMed ID: 16432856
[TBL] [Abstract][Full Text] [Related]
2. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
[TBL] [Abstract][Full Text] [Related]
3. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia.
Aslan DL; Peterson BA; Long-Tsai M; Eastlund T
Transfusion; 2006 Jan; 46(1):90-4. PubMed ID: 16398735
[TBL] [Abstract][Full Text] [Related]
4. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
Delannoy A; Ferrant A; Martiat P; Bosly A; Zenebergh A; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):317-20. PubMed ID: 7971252
[TBL] [Abstract][Full Text] [Related]
5. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
[TBL] [Abstract][Full Text] [Related]
6. Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Owen RG
Expert Opin Pharmacother; 2001 Jun; 2(6):945-52. PubMed ID: 11585010
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine.
Niesvizky R; Zhu AX; Louie D; Michaeli J
N Engl J Med; 1999 Jul; 341(1):55. PubMed ID: 10391760
[No Abstract] [Full Text] [Related]
8. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
9. [Bone changes in Waldenstrom's macroglobulinemia].
Novikova EZ; Mokeeva RA
Probl Gematol Pereliv Krovi; 1980 Apr; 25(4):26-9. PubMed ID: 6770363
[No Abstract] [Full Text] [Related]
10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
11. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 1996; 7 Suppl 6():S27-33. PubMed ID: 9010576
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of histological transformation events in Waldenström's macroglobulinemia (WM) and related disorders.
Owen RG; Bynoe AG; Varghese A; de Tute RM; Rawstron AC
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):176-9. PubMed ID: 21856554
[TBL] [Abstract][Full Text] [Related]
13. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
Jondeau K; Alterescu R; Franc B; Davi F; Massé JM; Boukour S; Le Parc JM; Cramer EM
Eur J Haematol; 2006 Jul; 77(1):74-9. PubMed ID: 16827885
[TBL] [Abstract][Full Text] [Related]
14. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
15. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T
Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature.
Madan RA; Chang VT; Yook C; Baddoura FK; Srinivas S; Kasimis B
Leukemia; 2004 Aug; 18(8):1433-5. PubMed ID: 15201850
[No Abstract] [Full Text] [Related]
17. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
20. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]